Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
RDAC (Redacted) volatility reaches 87.7% in 24 hours: registration upgrade countdown drives 60.7% surge in trading volume

RDAC (Redacted) volatility reaches 87.7% in 24 hours: registration upgrade countdown drives 60.7% surge in trading volume

Bitget PulseBitget Pulse2026/03/12 01:40
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, RDAC price rebounded from a low of $0.001167 to a high of $0.002190, with the current quote at $0.001376, representing a fluctuation amplitude of 87.7%. The 24-hour trading volume reached approximately $1.168 million, up 60.7% day-on-day, and trading activity for the RDAC/USDT pair on Bitget saw a notable increase.

Summary of Abnormal Movements

- Official upgrade registration countdown: Redacted Group announced that the migration/upgrade registration from $RDAC to $10SET will end at 9AM UTC on March 12, prompting token holders to withdraw from CEX and complete registration, which drove increased trading activity and price volatility.

- Community response: Over the past 24 hours, discussions on the X platform have been focused on wallet registration and the automatic conversion of RWA yields into $10SET, further strengthening market participation.

Market View and Outlook

Overall mainstream market sentiment remains positive, with the community emphasizing “upgrading registration lock-in opportunities” and “RWA yield strategies.” The increase in trading volume is seen as a sign of capital movements before the registration deadline. Analysts caution that there may be uncertainties after the registration and recommend monitoring official updates and on-chain registration data closely.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23